EP3541403A4 - Conjugués ligand-ionophore - Google Patents

Conjugués ligand-ionophore Download PDF

Info

Publication number
EP3541403A4
EP3541403A4 EP17871348.3A EP17871348A EP3541403A4 EP 3541403 A4 EP3541403 A4 EP 3541403A4 EP 17871348 A EP17871348 A EP 17871348A EP 3541403 A4 EP3541403 A4 EP 3541403A4
Authority
EP
European Patent Office
Prior art keywords
ligand
ionophore
conjugates
ionophore conjugates
ligand ionophore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17871348.3A
Other languages
German (de)
English (en)
Other versions
EP3541403A2 (fr
Inventor
Philip Stewart Low
Andrea L. KASINSKI
Loganathan RANGASAMY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of EP3541403A2 publication Critical patent/EP3541403A2/fr
Publication of EP3541403A4 publication Critical patent/EP3541403A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP17871348.3A 2016-11-16 2017-11-16 Conjugués ligand-ionophore Withdrawn EP3541403A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662422922P 2016-11-16 2016-11-16
US201762478063P 2017-03-29 2017-03-29
PCT/US2017/061997 WO2018094035A2 (fr) 2016-11-16 2017-11-16 Conjugués ligand-ionophore

Publications (2)

Publication Number Publication Date
EP3541403A2 EP3541403A2 (fr) 2019-09-25
EP3541403A4 true EP3541403A4 (fr) 2020-08-12

Family

ID=62146794

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17871348.3A Withdrawn EP3541403A4 (fr) 2016-11-16 2017-11-16 Conjugués ligand-ionophore

Country Status (4)

Country Link
EP (1) EP3541403A4 (fr)
JP (2) JP7116728B2 (fr)
CN (1) CN110167577B (fr)
WO (1) WO2018094035A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112010862B (zh) * 2020-10-23 2021-03-30 南京诺源医疗器械有限公司 一种主动靶向叶酸受体近红外荧光分子及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919928A (en) * 1984-05-23 1990-04-24 Sanofi Conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, their use as immunotoxin potentiators and the intermediate activated ionophores
WO2016183131A1 (fr) * 2015-05-11 2016-11-17 Purdue Research Foundation Conjugués ligand-ionophore

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2564839B1 (fr) * 1984-05-23 1986-11-14 Sanofi Sa Conjugues associant par liaison covalente un ionophore carboxylique monovalent et une macromolecule et leur utilisation comme agents potentialisateurs des immunotoxines
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US20070009434A1 (en) * 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
PL2187965T3 (pl) * 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US20120022245A1 (en) * 2008-10-17 2012-01-26 Purdue Research Foundation Folate targeting of nucleotides
US20110288152A1 (en) * 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9181375B2 (en) * 2011-02-14 2015-11-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fluorescent potassium ion sensors
WO2015130997A1 (fr) * 2014-02-26 2015-09-03 Gdovin Matthew Libération de proton nitrobenzaldéhyde pour la manipulation de l'acidose cellulaire
US9777279B2 (en) * 2014-09-24 2017-10-03 University Of Cincinnati Methods and compositions for treating autoimmune disorders by targeting Kv1.3 ion channels with functionalized lipid-derived nanovesicles
WO2015151078A2 (fr) * 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Lieurs hydrophiles pour conjugaison

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919928A (en) * 1984-05-23 1990-04-24 Sanofi Conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, their use as immunotoxin potentiators and the intermediate activated ionophores
WO2016183131A1 (fr) * 2015-05-11 2016-11-17 Purdue Research Foundation Conjugués ligand-ionophore

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
- PURDUE RESEARCH FOUNDATION: "Priority document WO2016/183131", 17 November 2016 (2016-11-17), XP055711394, Retrieved from the Internet <URL:https://patentscope.wipo.int/search/docs2/pct/WO2016183131/pdf/Mx1gAMEXGK9Hvd6ZHKIlmMhqVHFA3UeIkz7jPgAaSjUO-KiG3gKnIGHX96bXV1E91Mui7g7TDC0l7GJiVt2K2Hyp83NOwRyoc9JBXfha5Th1Ml4pFzCwGjg4I0yMZRvP?docId=id00000035639729> [retrieved on 20200702] *
ERINA VLASHI ET AL: "Effect of Folate-Targeted Nanoparticle Size on Their Rates of Penetration into Solid Tumors", ACS NANO, vol. 7, no. 10, 22 October 2013 (2013-10-22), US, pages 8573 - 8582, XP055711092, ISSN: 1936-0851, DOI: 10.1021/nn402644g *
ESTEBAN A ORELLANA ET AL: "FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer", 2 August 2017 (2017-08-02), XP055711066, Retrieved from the Internet <URL:https://stm.sciencemag.org/content/scitransmed/9/401/eaam9327.full.pdf> [retrieved on 20200702] *
ESTEBAN A ORELLANA ET AL: "Supplementary Information FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer", 2 August 2017 (2017-08-02), XP055711067, Retrieved from the Internet <URL:https://stm.sciencemag.org/content/scitransmed/suppl/2017/07/31/9.401.eaam9327.DC1/aam9327_SM.pdf> [retrieved on 20200702] *
GOOITZEN M VAN DAM ET AL: "Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-[alpha] targeting: first in-human results", NATURE MEDICINE, vol. 17, no. 10, 18 September 2011 (2011-09-18), New York, pages 1315 - 1319, XP055299051, ISSN: 1078-8956, DOI: 10.1038/nm.2472 *
MINI THOMAS ET AL: "Ligand-Targeted Delivery of Small Interfering RNAs to Malignant Cells and Tissues", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1175, no. 1, 1 September 2009 (2009-09-01), pages 32 - 39, XP055046132, ISSN: 0077-8923, DOI: 10.1111/j.1749-6632.2009.04977.x *

Also Published As

Publication number Publication date
CN110167577A (zh) 2019-08-23
JP2019535719A (ja) 2019-12-12
CN110167577B (zh) 2024-05-10
WO2018094035A3 (fr) 2018-06-28
JP2022166047A (ja) 2022-11-01
WO2018094035A2 (fr) 2018-05-24
EP3541403A2 (fr) 2019-09-25
JP7116728B2 (ja) 2022-08-10

Similar Documents

Publication Publication Date Title
EP3506913A4 (fr) Ligands de ciblage
EP3313857A4 (fr) Conjugués polymère-cyclodextrine-lipide
EP3445380B8 (fr) Bactériothérapie
EP3525808A4 (fr) Conjugués anticorps-polymère-médicament
EP3430033A4 (fr) Conjugués d&#39;insuline-incrétine
EP3496755A4 (fr) Conjugués d&#39;antagonistes de tgf- .
EP3464347A4 (fr) Stradomères optimisés par la cystéine
EP3405500A4 (fr) Maltosyl-isomaltooligosaccharides
EP3445347A4 (fr) Améliorations de la chimiothérapie
EP3623755A4 (fr) Règle
EP3463423A4 (fr) Conjugués glucagon-t3
EP3463229A4 (fr) Dispositif d&#39;ouverture de l&#39; il
EP3334447A4 (fr) Conjugués médicament-cck2r
EP3541403A4 (fr) Conjugués ligand-ionophore
EP3439755A4 (fr) Machine de tacle
EP3341022A4 (fr) Conjugués
EP3498711A4 (fr) Dérivé de morphinane
EP3479989A4 (fr) Buse de carotte
EP3421145A4 (fr) Machine pour le lavage de grains
AU2016904865A0 (en) Incentibuy
AU2016903308A0 (en) eKEBAB MACHINE
AU2016904425A0 (en) Neuro-Stimulant
AU2016903908A0 (en) fRecharge
AU2016903845A0 (en) RollAlong
AU2016903844A0 (en) Seedwalker

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200713

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/533 20060101ALI20200708BHEP

Ipc: A61K 38/08 20190101ALI20200708BHEP

Ipc: A61K 49/00 20060101AFI20200708BHEP

Ipc: A61K 31/7088 20060101ALI20200708BHEP

Ipc: A61P 35/00 20060101ALI20200708BHEP

Ipc: A61K 47/55 20170101ALI20200708BHEP

Ipc: G01N 33/84 20060101ALI20200708BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40018369

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210210